Labcorp公布2026年二季度业绩并上调全年营收和调整后EPS指引

PDF Version
Results from operations for second quarter 2026 versus second quarter 2025:
Revenue:
$3.73 billion
vs.
$3.53 billion
, up 5.8%
Diluted EPS:
$3.64
vs.
$2.84
, up 28.5%
Adjusted EPS:
$4.99
vs.
$4.35
, up 14.9%
Raised full-year enterprise revenue growth and adjusted EPS guidance:
Annual revenue growth guidance of 5.4% to 6.3%; up 30 basis points at the midpoint
Adjusted EPS range of
$18.10
to
$18.55
; up
30 cents
at the midpoint
Announced
$1.0 billion
increase in share repurchase authorization, bringing the remaining total authorization to
$1.4 billion
Advanced Labcorp Oncology offerings in lung, colorectal, and prostate cancers, expanding access to screening, improving diagnosis, guiding treatment selection, and monitoring recurrence
Announced the launch of Marker by Labcorp™, a genetic health panel that provides consumers with personalized genetic insights
BURLINGTON, N.C.
,
July 30, 2026
/PRNewswire/ --
Labcorp Holdings Inc.
(NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended
June 30, 2026
and updated its full-year financial guidance.
"
Labcorp
delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth reflecting continued momentum across the business," said
Adam Schechter
, Chairman and CEO of
Labcorp
. "During the second quarter, we expanded our leadership in oncology and other high-growth specialty areas, strengthened our position as the partner of choice for health systems, biopharmaceutical companies, and regional/local laboratories, and advanced our use of technology to improve the experience for consumers and providers. Our performance and continued execution position us well to deliver sustainable growth and long-term value for customers and shareholders."
Labcorp
continues to advance its strategic priorities:
Lead in specialty testing, with several advancements in Labcorp Oncology:
Added an advanced DPYD genotyping test that helps identify patients at risk for severe chemotherapy treatment-related toxicity.
Launched ColoSense® nationwide, the first FDA-approved, RNA-based colorectal cancer screening test with at-home collection. With Medicare and expanding commercial payer coverage, this test increases patient access to screening and enables earlier detection. As ColoSense's primary nationwide distributor, we are further strengthening our comprehensive colorectal cancer portfolio.
Entered into a clinical trial collaboration with
Fox Chase Cancer Center
to evaluate
Labcorp's
Plasma Detect Genome MRD in patients at risk of early-stage non-small cell lung cancer recurrence.
Expanded nationwide access to Roche's FDA-approved VENTANA PTEN (SP218) companion diagnostic for people living with prostate cancer who may now be eligible for combination treatment with AstraZeneca's targeted therapy TRUQAP.
Be a partner of choice for health systems and regional/local laboratories:
Awarded once again a
Department of Defense
contract to provide laboratory testing for service members and their families across military hospitals worldwide.
Completed the acquisition of select outreach laboratory services from
Parkview Health
in
Indiana
and
Ohio
.
Completed the acquisition of
Tribal Diagnostics
, a clinical laboratory serving communities in
Oklahoma
and
Texas
.
Grow Consumer Health
:
Announced the Marker by
Labcorp Genetic Health Panel
through Labcorp OnDemand where consumers can get their biomarker and genetic testing and insights from a single source.
Introduced
Canada's
first at-home, self-collection test to measure women's fertility-related hormones and men's testosterone levels.
Launched an AI-powered app, MyLabcorp, which has been downloaded by millions of consumers. The app allows patients to schedule appointments, view their test results, and gain deeper insights into their health.
Shape our future through technology and innovation:
Expanded a collaboration with Epic to place 6,500-plus diagnostic tests on Epic's Aura platform.
Enhanced the patient experience at
Labcorp's
Patient Service Centers
, through expanded appointment availability, streamlined scheduling, and proactive rescheduling reminders and assistance.
Labcorp
also remains committed to a disciplined allocation of capital. In the second quarter of 2026, the company invested
$225.7 million
in acquisitions, repurchased
$353.8 million
of stock, and paid out
$58.7 million
in dividends. The company also paid down
$500.0 million
in senior notes in June. On
July 9, 2026
, the company announced a quarterly cash dividend of
$0.72
per share of common stock, payable on
September 11, 2026
, to stockholders of record at the close of business on
August 28, 2026
. In July, the Board of Directors approved an increase of
$1.0 billion
in the company's share repurchase authorization, bringing the remaining total authorization to
$1.4 billion
.
LABCORP HOLDINGS INC.
AND SUBSIDIARIES
CONSOLIDATED RESULTS
Three Months Ended
June 30
,
Six Months Ended
June 30
,
2026
2025
Delta
2026
2025
Delta
Revenue Summary
(Dollars in millions)
Total Revenue
$ 3,731.1
$ 3,527.3
5.8 %
$ 7,268.7
$ 6,872.4
5.8 %
Organic
(1)
4.2 %
3.6 %
Acquisitions, net of Divestitures
(2)
1.2 %
1.3 %
Foreign Exchange
0.4 %
0.9 %
(1)
Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in
Early Development
.
(2)
Includes the impact from strategic actions taken in
Early Development
.
Earnings Summary
(Dollars in millions, except per share data)
Operating Income ("OI")
$   451.6
$   394.5
$    832.4
$    720.5
OI as % of Revenue
12.1 %
11.2 %
90 bps
11.5 %
10.5 %
100 bps
Adjustments
(3)
$   137.1
$   137.1
$    264.2
$    280.1
Adjusted Operating Income  ("AOI")
(4)
$   588.7
(5)
$   531.6
$ 1,096.6
$ 1,000.6
AOI as % of Revenue
15.8 %
(5)
15.1 %
70 bps
15.1 %
14.6 %
50 bps
Net Earnings Attributable to Labcorp
Holdings Inc.
$   298.7
$   237.9
$   576.5
$   450.7
Diluted EPS
$     3.64
$     2.84
$     6.99
$     5.36
Adjusted EPS
(4)
$     4.99
$     4.35
14.9 %
$     9.24
$     8.19
12.8 %
(3)
Adjustments include amortization, impairment charges, restructuring charges, and special items.
(4)
Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.
(5)
The increase in adjusted operating income and margin was due to organic growth and operating efficiencies.
LABCORP HOLDINGS INC.
AND SUBSIDIARIES
CONSOLIDATED RESULTS
Three Months Ended
June 30
,
Six Months Ended
June 30
,
2026
2025
2026
2025
Cash Flow Summary
(Dollars in millions)
Operating Cash Flow
$        445.5
$        620.6
$         637.0
$         639.1
Capital Expenditures
131.6
77.9
252.6
203.9
Free Cash Flow
$        313.9
(1)
$        542.7
$         384.4
$         435.2
(1)
The difference in free cash flow was primarily due to working capital timing and planned increases in capital expenditures.
Capital Allocation Summary
At the end of the quarter,
Labcorp's
cash and cash equivalents balance was
$141
.8 million and total debt was
$5
.86 billion.  In June, we retired
$500.0 million
in senior notes.
During the quarter, the company invested
$225.7 million
in acquisitions, repurchased
$353.8 million
of stock, and paid out
$58.7 million
in dividends.
LABCORP HOLDINGS INC.
AND SUBSIDIARIES
Diagnostics Laboratories Segment Summary
Three Months Ended
June 30
,
2026
2025
Delta
Revenue Summary
(Dollars in millions)
Total Revenue
$           2,900.7
$           2,748.8
5.5 %
Organic
3.6 %
Acquisitions, net of Divestitures
1.9 %
Earnings Summary
(1)
(Dollars in millions)
Adjusted Operating Income ("AOI")
(2)
$ 522.6
(3)
$ 482.8
AOI as % of Revenue
18.0 %
(3)
17.6 %
50 bps
(1)
Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.
(2)
Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.
(3)
Adjusted Operating Income and margin increased due to organic growt